PMC9996216_01
Daily fondaparinux doses and anti-Xa trough levels. Anti-Xa in IU/mL for patient (A) (assay calibrated for low molecular-weight heparins), in mg/L for patients (B, C); # means peak anti-Xa 3 h after administration (trough levels were taken max. 2 h before the next dose); x-axis represents days after HIT diagnosis and commencement of fondaparinux treatment.
fmed-10-1112770-g0001.jpg
PMC9996216_03_fmed-10-1112770-g0001.jpg
F1
Trough anti-Xa levels were also determined by fondaparinux-calibrated assay (Figure 1C).
Daily platelet count and markers of ECMO circuit thrombosis. x-axis represents days after HIT diagnosis and commencement of fondaparinux treatment. (A-C) represent individual patients.
fmed-10-1112770-g0002.jpg
PMC9996216_03_fmed-10-1112770-g0002.jpg
F2
Due to an increase in DeltaP (Figure 2C) with concomitant deterioration of blood gases, the ECMO circuit was exchanged on day 2. Fibrin deposits, detected in the oxygenator on day 22, were accompanied by a mild increase in DeltaP and plasma free hemoglobin (Figure 2C).
PMC9996216_02
Daily fondaparinux doses and anti-Xa trough levels. Anti-Xa in IU/mL for patient (A) (assay calibrated for low molecular-weight heparins), in mg/L for patients (B, C); # means peak anti-Xa 3 h after administration (trough levels were taken max. 2 h before the next dose); x-axis represents days after HIT diagnosis and commencement of fondaparinux treatment.
fmed-10-1112770-g0001.jpg
PMC9996216_03_fmed-10-1112770-g0001.jpg
F1
Trough anti-Xa levels were also determined by fondaparinux-calibrated assay (Figure 1C).
Daily platelet count and markers of ECMO circuit thrombosis. x-axis represents days after HIT diagnosis and commencement of fondaparinux treatment. (A-C) represent individual patients.
fmed-10-1112770-g0002.jpg
PMC9996216_03_fmed-10-1112770-g0002.jpg
F2
Due to an increase in DeltaP (Figure 2C) with concomitant deterioration of blood gases, the ECMO circuit was exchanged on day 2. Fibrin deposits, detected in the oxygenator on day 22, were accompanied by a mild increase in DeltaP and plasma free hemoglobin (Figure 2C).
PMC9996216_03
Daily fondaparinux doses and anti-Xa trough levels. Anti-Xa in IU/mL for patient (A) (assay calibrated for low molecular-weight heparins), in mg/L for patients (B, C); # means peak anti-Xa 3 h after administration (trough levels were taken max. 2 h before the next dose); x-axis represents days after HIT diagnosis and commencement of fondaparinux treatment.
fmed-10-1112770-g0001.jpg
PMC9996216_03_fmed-10-1112770-g0001.jpg
F1
Trough anti-Xa levels were also determined by fondaparinux-calibrated assay (Figure 1C).
Daily platelet count and markers of ECMO circuit thrombosis. x-axis represents days after HIT diagnosis and commencement of fondaparinux treatment. (A-C) represent individual patients.
fmed-10-1112770-g0002.jpg
PMC9996216_03_fmed-10-1112770-g0002.jpg
F2
Due to an increase in DeltaP (Figure 2C) with concomitant deterioration of blood gases, the ECMO circuit was exchanged on day 2. Fibrin deposits, detected in the oxygenator on day 22, were accompanied by a mild increase in DeltaP and plasma free hemoglobin (Figure 2C).